OV to evaluate the potential of in-licensing a small molecule compound for development in cancer from a major Pharmaceutical company
Hoersholm, Denmark, July 19th, 2017 – Oncology Venture AB (OV:ST) and Novartis Pharma AG (Basel, Switzerland) have entered into an agreement providing Oncology Venture with an option right to execute an exclusive license to develop and commercialize an undisclosed small molecule, kinase inhibitor in clinical development. The molecule has been explored in multiple therapeutic indications including a variety of solid tumors. Further terms of the agreement were not disclosed.Under the option agreement, OV will evaluate whether it can suitably develop and validate a companion diagnostic for